Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ondansetron reduces the craving of biologically predisposed alcoholics.

Psychopharmacology - 1 Apr 2002

Johnson Bankole A, Roache John D, Ait-Daoud Nassima, Zanca Nursen A, Velazquez Madeline

Abstract excerpt

RATIONALE: Early onset alcoholics (EOA) differ from late onset alcoholics (LOA) by having greater serotonergic abnormality, familial history, and a range of antisocial behaviors. Previously, we showed that ondansetron, a selective 5-HT3 antagonist, effectively treated EOA. Proximate motivational drives such as craving could have determined drinking behavior. We therefore investigated whether ondansetron treatment...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alcoholism
Share to Analysis of Variance
Share to Behavior, Addictive

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Chi-Square Distribution

Share to Double-Blind Method

Share to Serotonin Antagonists

Share to Severity of Illness Index

Share to Single-Blind Method

Source

Identifiers

PMID: 11919668
DOI: 10.1007/s00213-002-1002-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ondansetron reduces the craving of biologically predisposed alcoholics.PMID 11919668Read ↗

A Phase 3 Randomized Precision Medicine Clinical Trial Using Low-Dose Ondansetron (a 5-HT3 Antagonist) to Treat Alcohol Use DisorderSemantic proximity Read ↗

A Prospective Pharmacogenetic Phase 3 Clinical Trial of Low-Dose Ondansetron (A 5-HT3 Antagonist) to Treat Heavy and Very Heavy Drinkers With Alcohol Use DisorderSemantic proximity Read ↗

A Prospective Precision Medicine Phase 3 Clinical Trial of Low-dose Ondansetron (a 5-ht3 Antagonist) to Treat Heavy and Very Heavy Drinkers With Alcohol Use DisorderSemantic proximity Read ↗

Current Pharmacotherapies for Alcohol Use Disorder in Italy: From Neurobiological Targets to Clinical PracticeSemantic proximity Read ↗

Commentary on Efficacy and Safety of Low dose ondansetron as a prospective precision medicine to treat alcohol use disorder phenotypes.Semantic proximity Read ↗

Serotonergic agents and alcoholism treatment: a simulation.Semantic proximity Read ↗

Neuro-chemical activation of brain reward meso-limbic circuitry is associated with relapse prevention and drug hunger: a hypothesis.Semantic proximity Read ↗

Neurobiological correlates of the disposition and maintenance of alcoholism.Semantic proximity Read ↗

Advances in the use of naltrexone: an integration of preclinical and clinical findings.Semantic proximity Read ↗

Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking.Semantic proximity Read ↗

Ondansetron and sertraline may interact with 5-HTTLPR and DRD4 polymorphisms to reduce drinking in non-treatment seeking alcohol-dependent women: exploratory findings.Semantic proximity Read ↗

Clinical correlates of craving among patients seeking treatment for substance use disorderSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.